Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:41:00.533Z.
Calculation as of: 2026-10-06T15:41:00.533Z.
Quote observation: 2026-10-06T15:40:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2a39ca6935a26d8aa5af55aa8ea7db8fcfa7d32011c972ec9cce8dd9481767f6
PEG RATIO
N/A
BridgeBio Oncology Therapeutics Inc.
Market Cap
$291.19M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $291.19M | N/A |
| Standard BioTools Inc. (LAB)vs › | $291.48M | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.54M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $287.63M | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $297.62M | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.44M | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $278.58M | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $304.72M | N/A |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $310.71M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
